Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.
Maxmen
Amy
A
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004249:DNA Damage / Q000187:drug effects; D015254:DNA Modification Methylases / Q000187:drug effects* / Q000235:genetics; D004260:DNA Repair / Q000187:drug effects*; D045643:DNA Repair Enzymes / Q000187:drug effects* / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D019398:Genes, BRCA1 / Q000187:drug effects; D024522:Genes, BRCA2 / Q000187:drug effects; D006579:Heterozygote; D006801:Humans; D009154:Mutation / Q000187:drug effects; D010793:Phthalazines / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D025521:Tumor Suppressor Proteins / Q000187:drug effects* / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D025521:Tumor Suppressor Proteins; C090712:iniparib; D015254:DNA Modification Methylases; C515491:MGMT protein, human; C499320:PARP1 protein, human; D000071137:Poly (ADP-Ribose) Polymerase-1; D045643:DNA Repair Enzymes; C531550:olaparib